UNIVERSITE VICTOR SEGALEN BORDEAUX 2 Patent applications |
Patent application number | Title | Published |
20140308343 | METHOD FOR PREPARING NANOPARTICLES BASED ON FUNCTIONAL AMPHIPHILIC MOLECULES OR MACROMOLECULES, AND THE USE THEREOF - The invention relates to a method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, optionally in the presence of at least one colipide, enabling the encapsulation of therapeutic agents, especially anti-tumoral agents, and the use thereof for the transport and vectorization of therapeutic agents, especially anti-tumoral agents. | 10-16-2014 |
20130298917 | AIR-PERMEABLE ADAPTABLE MOUTHGUARD HAVING CLAMPED JAWS - A mouthguard able to be shaped in the mouth, has an adaptable structure consisting of an adaptable material, and a skeleton, at least partially covered by the adaptable structure, consisting of a non-adaptable material. The mouthguard also has a removable pallet consisting of a non-adaptable material and comprising a first region intended to butt against the skeleton, the region of the pallet being dimensioned such that, during the adaption phase of the mouthguard, the combined presence of the pallet and of the skeleton ensures both ventilation space and the presence of sufficient material at the incisor-canine area. | 11-14-2013 |
20130131181 | USE OF A BETA BLOCKER FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HEMANGIOMAS - The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas. | 05-23-2013 |
20130072551 | USE OF A BETA BLOCKER FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HEMANGIOMAS - The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas. | 03-21-2013 |
20120122916 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES - The invention concerns screening molecules with anti-prion activity. More particularly, it concerns kits for screening molecules with anti-prion activity characterized in that they comprise in combination a [PSI+], phenotype yeast, an antibiogram and an agent for purifying prions at sub-efficient doses, said yeast including the ade1-14 allele of the ADE1 gene and an inactivated ERG6 gene, the screening methods, and a family of molecules with anti-prion activity isolated by the inventive screen. The invention is applicable to anti-prion agents for producing medicines in particular for treating neurodegenerative diseases involving protein aggregates. | 05-17-2012 |
20120034210 | COMPOSITIONS FOR POTENTIATING APOPOSIS SIGNALS IN TUMOUR CELLS - The present invention concerns a composition for potentiating formation of DISC (Death Inducing Signaling Complex) macro-complex and for inducing apoptotic signal mediated by death receptors in tumour cells comprising a therapeutically effective amount of an active agent selected among a hypocalcemia-inducing agent, a calcium channel inhibitor and a calcium chelator in association with a therapeutically effective amount of an anticancer agent inducing an apoptotic signal via death receptors Fas, TNF-R1, DR4 and/or DR5. | 02-09-2012 |
20110092483 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES - A kit and a method for identifying compounds having anti-prion activity are provided. The kit comprises a yeast of phenotype [PSI+]; an antibiogram; and a prion curing agent in a sub-effective dose, wherein the yeast has the adel-14 allele of the ADE1 gene and an inactivated ERG6 gene. Compounds and pharmaceutical compositions having anti-prion activity are also provided, which are useful for treating various neurodegenerative diseases, including polyglutamines expansion associated diseases; Huntington's disease; Kennedy disease; amyotrophic lateral sclerosis; cerebellous autosomic ataxies; dentalorubral-pallidoluysian atrophy; and spino-bulbar amyotrophy. | 04-21-2011 |
20110015255 | TREATMENT OF AN INFECTION BY AN RNA VIRUS DUE TO AN RNA DEPENDENT RNA POLYMERASE - The present invention concerns a simple RNA strand, which includes, from extremity 3′ to extremity 5′, (i) a sequence of complementary nucleic acid to the non-coding region 5′ (5′UTR) of the genomic RNA (strand (+)) of the hepatitis C virus (VHC) or another RNA virus replicating thanks to an RNA dependent RNA polymerase, the nucleic acid sequence of which allows the replication of said simple RNA strand molecule by the replication complex of said virus, (ii) the complementary nucleic acid sequence of a corresponding nucleic acid sequence from the site of internal entry of the ribosome (1RES), and (iii) the complementary nucleic acid sequence of a suicide gene or a coding gene for a protein interfering with the replication of the VHC virus or another RNA virus replicating thanks to an RNA dependent RNA polymerase; an ADN molecule allowing the transcription of said simple RNA strand molecule; a vector of nucleic acids including said molecules of nucleic acids; and a pharmaceutical compound including said molecules of nucleic acids or said vector of nucleic acid. | 01-20-2011 |
20100273889 | USE OF A BETA BLOCKER FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HEMANGIOMAS - The present invention relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present invention provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas. | 10-28-2010 |
20100136040 | USE OF THE 7F4 PROTEIN IN THE IN VITRO DIAGNOSIS OF MYCOPLASMA PNEUMONIAE INFECTIONS - A method for determining if an individual is infected by | 06-03-2010 |
20100021955 | MODELLING IN YEAST OF THE MITOCHONDRIAL ATP6 GENE MUTATIONS RESPONSIBLE FOR NARP SYNDROME IN HUMANS AND USES THEREOF FOR SCREENING FOR MEDICAMENTS - Modified yeast cells comprising at least one mutation of the tryptophan 136 (W | 01-28-2010 |
20090318413 | BRONCHIAL SMOOTH MUSCLE REMODELING INVOLVES CALCIUM-DEPENDENT ENHANCED MITOCHONDRIAL BIOGENESIS IN ASTHMA - The present invention thus provides a method of inhibiting bronchial smooth muscle remodeling in asthma, comprising the step of administering to a subject having asthma an agent that inhibits calcium-dependent mitochondrial biogenesis. | 12-24-2009 |
20090275497 | METHOD FOR IDENTIFYING MODULATORS OF THE ACTIVITY OF ION-CHANNELS RECEPTORS - The present invention is directed to a method for selecting or identifying a compound capable of modulating the activity of an ion-channels receptor, such as GABA receptor, by measuring the calcium influx via the P2X receptor in presence of its agonist ATP when coupled to said ion-channels receptor in recombinant cells coexpressing these two receptors. The invention also concerns a kit or a device comprising the essentiel elements to perform the method according to the invention. Finally, the present invention is directed to the use of said selected compounds for the prevention or the treatment of diseases related to said ion-channels receptor dysfunction. | 11-05-2009 |
20090012514 | Device for Positioning the Energy-Generating Means of an Assembly for the Heat Treatment of Biological Tissues - The invention relates to a device for positioning the energy-generating means of an assembly for the heat treatment of biological tissues, whereby the energy-generating means are adapted to emit energy in one aiming direction which is located in an aiming plane. The inventive device is characterized in that it comprises movement means which can alter the position of the energy-generating means and, consequently, the aiming direction in the aiming plane around a target zone within said aiming plane. | 01-08-2009 |